Stephanie McQuillin, APRN
Family · Wasilla, AKNPI 1023503570
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,109 of the $4,047 with a category attached, or 76.8%. Calliditas Therapeutics US Inc. accounts for 79.7% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $3,638, more than ten times the $102 reported in 2021. Among family clinicians in AK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 52 payments — averaging $77.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calliditas Therapeutics US Inc.$3K
- Novartis$260
- AstraZeneca$169
- Otsuka America Pharmaceutical, Inc.$95
- Vifor Pharma, Inc.$65
- Akebia Therapeutics Inc$44
- plus $192 from 7 others
What the payments were for
- Consulting fees$3,10977%
- Food & beverage$93723%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Calliditas Therapeutics US Inc. | 6 | $3,223 |
| Novartis | 23 | $260 |
| AstraZeneca(2 entities) | 4 | $169 |
| Otsuka America Pharmaceutical, Inc. | 4 | $95 |
| Vifor Pharma, Inc. | 2 | $65 |
| Akebia Therapeutics Inc | 2 | $44 |
| Fresenius USA Marketing, Inc. | 2 | $42 |
| Bayer | 2 | $35 |
| Ardelyx, Inc. | 2 | $32 |
| Mallinckrodt Hospital Products Inc. | 1 | $31 |
| Amgen | 1 | $30 |
| Novo Nordisk | 1 | $13 |
| Travere Therapeutics, Inc. | 2 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TARPEYO$3,109
How this compares
$4,047 in reported general payments places this provider in the 90th percentile of 315 family providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 39 | $51,248 |
| OzempicSemaglutide | 29 | $43,542 |
| Cinacalcet Hcl | 31 | $24,956 |
| Sevelamer Carbonate | 28 | $22,864 |
| EliquisApixaban | 13 | $22,026 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $21,031 |
| TradjentaLinagliptin | 24 | $20,837 |
| JardianceEmpagliflozin | 12 | $19,612 |
| RetacritEpoetin Alfa-Epbx | 12 | $5,083 |
| Tacrolimus | 64 | $3,397 |
| Nifedipine ErNifedipine | 58 | $3,379 |
| Pentoxifylline | 82 | $2,447 |
| Clonidine | 15 | $2,244 |
| Tamsulosin Hcl | 71 | $2,198 |
| Atorvastatin Calcium | 168 | $1,964 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $169 | $51,24839 claims |
| Novo NordiskOzempic | $13 | $43,54229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 315 family providers in Alaska.
Other family in Wasilla
- Kymberli BrockWasilla$5K
- Sarah NielsenWasilla$4K
- Alison ArmourWasilla$4K
- Liudmila FedorWasilla$4K
- Debby MaloneyWasilla$3K
- Alysa SonnentagWasilla$3K
- Christine BailesWasilla$2K
- Lisa Bouyea-FranciesWasilla$2K
- Kathleen MatthewsWasilla$2K
- Erica MuchaWasilla$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.